Delving into the Latest Updates on TMC-69 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

Mitsubishi Tanabe Pharma Corp.

Active Organization-

Inactive Organization

Mitsubishi Tanabe Pharma Corp.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

The unexpected selectivity profile of (17R)- and (17S)-TMC-69-6H suggests that N-hydroxypyridone derivatives constitute a promising new lead structure in the search for selective phosphatase inhibitors.An unprecedented Pd-catalyzed C-C bond formation to a pyranone derivative to form I was a key step in the synthesis of enantiopure (17R)- (II) and (17S)-TMC-69-6H.

01 Jan 2001·The Journal of AntibioticsQ4 · MEDICINE

TMC-69, a New Antitumor Antibiotic with Cdc25A Inhibitory Activity, Produced by Chrysosporium sp. TC1068.

Q4 · MEDICINE

Article

Author: Kimio Kawano ; Noboru Kishi ; Maki Nishio ; Toru Okuda ; Shiho Tsunoda ; Jun Kohno ; Saburo Komatsubara ; Naomitsu Hirano ; Noriyuki Nakanishi

A new antibiotic designated TMC-69 has been isolated from the fermentation broth of a fungal strain Chrysosporium sp. TC 1068. TMC-69 exhibited moderate in vitro cytotoxic activity. TMC-69-6H, a derivative of TMC-69 prepared by hydrogenation, possessed more potent in vitro cytotoxicity than TMC-69, and exhibited in vivo antitumor activity against murine P388 leukemia and B16 melanoma. TMC-69-6H was found to specifically inhibit Cdc25A and B phosphatases.

100 Deals associated with TMC-69

Login to view more data